RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RDW on youtube posted todayBenedictus said " Doctors are excited to integrate Adstiladrin into their treatment protocol".
After reading this link, I have big doubts about Adstiladrin being a serious competitor to TLT-Ruvidar.
https://drugs.com/drug-interactions/nadofaragene-firadenovec,adstiladrin.html It is said " There are 274 drugs know to interact with Adstiladrin, along with one disease(immunosuppression). Of the total drug interactions,
274 are major".
274 drugs interactions are major, looks very bad for Adstiladrin.
Why...
-Older patients are more prone to taking multiple drug(10-20).
-Most drug will be out of your system quite quickly, but older patients with kidney or liver problems can continue to have elevated blood level of a drug for extended period of time after stopping it.
-Because of these
274 major drug interactions, many older patients will not be eligible for Adstiladrin treatment.
TLT-Ruvidar(36%CR) is 100% safe and has no major drugs interactions and is 50% more potent than Adstiladrin(24%CR).
In short TLT-Ruvidar is the best and safest treatment for older bladder cancer patients.
Benedictus wrote: Legit62 wrote: Thats very plausible because our treatment for cancer is probably safest,best, least side affects and least number of treatments to come along in more than a decade. The scare factor right now with this PDT treatment is past PDT treatments didnt work, so some are scared off, once we get BTD and AA we roll. Now its just patience
I actually wonder if the current "concern factor" is more about the perceived "learning curve" for ruvidar treatment mentioned by Kulkarni and whether there is a question as to commercial viability of a left of center protocol, especially when you read how excited these doctors are about the ease of integrating adstiladrin into their treatment protocol. There appears to be some preference bias to an ease of administering protocol that ruvidar's durability and tolerability will have to overcome by a solid margin. I also wonder if this "learning curve" is the reason why so few patients are being enrolled in this study.